Today and Tomorrow: The Use of Biomarkers in Inflammatory Bowel Disease
DOI:
https://doi.org/10.58931/cibdt.2023.1320Abstract
Biomarkers play important roles in clinical care for people with inflammatory bowel diseases (IBD). Biomarkers are also central to the development of new therapies and as endpoints in their evaluation.
The recommendations from the STRIDE-II study emphasize the central role of clinical indices and biomarkers such as fecal calprotectin (FC) and C-reactive protein (CRP) in the management of Crohn’s disease (CD) and ulcerative colitis (UC).
This review will focus on the established roles for FC and CRP, emerging roles for alternative and composite biomarkers, limitations of current biomarkers, and unmet needs in the field. This is an evolving area, with recent clinical practice guidelines from the American Gastroenterological Association in UC. In addition, updates are expected from the European Crohn’s and Colitis Organisation on their multi-society guideline for IBD monitoring.
References
Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. DOI: https://doi.org/10.1053/j.gastro.2020.12.031
Singh S, Ananthakrishnan AN, Nguyen NH, Cohen BL, Velayos FS, Weiss JM, et al. AGA Clinical Practice Guideline on the role of biomarkers for the management of ulcerative colitis. Gastroenterology. 2023;164(3):344-372. DOI: https://doi.org/10.1053/j.gastro.2022.12.007
Rimmer P, Cheesbrough J, Quraishi MN, Sharma N, Cooney R, Love M, et al. P126 Ask twice: The importance of repeated faecal calprotectin testing prior diagnostic colonoscopy in an adult inception cohort. Journal of Crohn's and Colitis. 2023;17(Supplement_1):i291-i293. DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0256
Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, et al. From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol. 2018;24(33):3681-3694. DOI: https://doi.org/10.3748/wjg.v24.i33.3681
Mañosa Ciria M, Oller B, Garcia-Planella E, Guardiola J, Cañete F, Gonzalez Muñoza C, et al. P694 Long-term monitoring of post-surgical recurrence in Crohn's disease using a strategy based on the periodic determination of fecal calprotectin in patients without early postoperative recurrence. Journal of Crohn's and Colitis. 2023;17(Supplement_1):i824-i825. DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0824
Jung ES, Lee SP, Kae SH, Kim JH, Kim HS, Jang HJ. Diagnostic accuracy of fecal calprotectin for the detection of small bowel crohn's disease through capsule endoscopy: an updated meta-analysis and systematic review. Gut Liver. 2021;15(5):732-741.
D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, et al. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J. 2021;9(4):451-460. DOI: https://doi.org/10.1002/ueg2.12069
Haisma SM, Galaurchi A, Almahwzi S, Adekanmi Balogun JA, Muller Kobold AC, van Rheenen PF. Head-to-head comparison of three stool calprotectin tests for home use. PLoS One. 2019;14(4):e0214751. DOI: https://doi.org/10.1371/journal.pone.0214751
Ostlund I, Werner M, Karling P. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease. Scand J Gastroenterol. 2021;56(1):38-45. DOI: https://doi.org/10.1080/00365521.2020.1854342
Alghoul Z, Yang C, Merlin D. The current status of molecular biomarkers for inflammatory bowel disease. Biomedicines. 2022;10(7). DOI: https://doi.org/10.3390/biomedicines10071492
Bhagavathula AS, Clark CCT, Rahmani J, Chattu VK. Impact of body mass index on the development of inflammatory bowel disease: a systematic review and dose-response analysis of 15.6 million participants. Healthcare (Basel). 2021;9(1). DOI: https://doi.org/10.3390/healthcare9010035
Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(3):444-454. DOI: https://doi.org/10.1038/ajg.2015.6
Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817-1826.e1812. DOI: https://doi.org/10.1053/j.gastro.2010.11.058
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426-431. DOI: https://doi.org/10.1136/gut.2005.069476
Bertani L, Mumolo MG, Tapete G, Albano E, Baiano Svizzero G, Zanzi F, et al. Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. Eur J Gastroenterol Hepatol. 2020;32(9):1091-1098. DOI: https://doi.org/10.1097/MEG.0000000000001731
Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38(6):905-910. DOI: https://doi.org/10.1136/gut.38.6.905
Moore AC, Bressler B. Acute severe ulcerative colitis: The Oxford Criteria no longer predict in-hospital colectomy rates. Dig Dis Sci. 2020;65(2):576-580. DOI: https://doi.org/10.1007/s10620-019-05668-6
Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779-2789. DOI: https://doi.org/10.1016/S0140-6736(17)32641-7
Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, et al. Deep remission at 1 year prevents progression of early crohn's disease. Gastroenterology. 2020;159(1):139-147. DOI: https://doi.org/10.1053/j.gastro.2020.03.039
Lakatos PL, Kaplan GG, Bressler B, Khanna R, Targownik L, Jones J, et al. Cost-effectiveness of tight control for crohn's disease with adalimumab-based treatment: economic evaluation of the CALM Trial from a Canadian Perspective. J Can Assoc Gastroenterol. 2022;5(4):169-176. DOI: https://doi.org/10.1093/jcag/gwac001
Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hebuterne X, et al. P274 Factors driving treatment escalation in Crohn’s disease in the CALM trial. Journal of Crohn's and Colitis. 2018;12(supplement_1):S239-S239. DOI: https://doi.org/10.1093/ecco-jcc/jjx180.401
Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, et al. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol. 2022;7(4):294-306. DOI: https://doi.org/10.1016/S2468-1253(21)00474-X
Brand EC, Elias SG, Minderhoud IM, van der Veen JJ, Baert FJ, Laharie D, et al. Systematic review and external validation of prediction models based on symptoms and biomarkers for identifying endoscopic activity in crohn's disease. Clin Gastroenterol Hepatol. 2020;18(8):1704-1718. DOI: https://doi.org/10.1016/j.cgh.2019.12.014
Minderhoud IM, Steyerberg EW, van Bodegraven AA, van der Woude CJ, Hommes DW, Dijkstra G, et al. Predicting endoscopic disease activity in crohn's disease: a new and validated noninvasive disease activity index (the Utrecht Activity Index). Inflamm Bowel Dis. 2015;21(10):2453-2459. DOI: https://doi.org/10.1097/MIB.0000000000000507
Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, et al. Approaches to integrating biomarkers into clinical trials and care pathways as targets for the treatment of inflammatory bowel diseases. Gastroenterology. 2019;157(4):1032-1043.e1031. DOI: https://doi.org/10.1053/j.gastro.2019.06.018
Dragoni G, Innocenti T, Galli A. Biomarkers of inflammation in inflammatory bowel disease: how long before abandoning single-marker approaches? Dig Dis. 2021;39(3):190-203. DOI: https://doi.org/10.1159/000511641
Cozijnsen MA, Ben Shoham A, Kang B, Choe BH, Choe YH, Jongsma MME, et al. Development and validation of the mucosal inflammation noninvasive index for pediatric Crohn's disease. Clin Gastroenterol Hepatol. 2020;18(1):133-140.e131. DOI: https://doi.org/10.1016/j.cgh.2019.04.012
Magro F, Estevinho MM, Catalano G, Patita M, Arroja B, Lago P, et al. How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study. United European Gastroenterol J. 2023;11(6):531-541. DOI: https://doi.org/10.1002/ueg2.12420
Naganuma M, Kobayashi T, Nasuno M, Motoya S, Kato S, Matsuoka K, et al. Significance of conducting 2 types of fecal tests in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(5):1102-1111.e1105. DOI: https://doi.org/10.1016/j.cgh.2019.07.054
Ahmed I, Greenwood R, Costello B, Ratcliffe N, Probert CS. Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Aliment Pharmacol Ther. 2016;43(5):596-611. DOI: https://doi.org/10.1111/apt.13522
Arai Y, Arihiro S, Matsuura T, Kato T, Matsuoka M, Saruta M, et al. Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis. Inflamm Bowel Dis. 2014;20(7):1208-1216. DOI: https://doi.org/10.1097/MIB.0000000000000062
Sakurai T, Saruta M. Positioning and usefulness of biomarkers in inflammatory bowel disease. Digestion. 2023;104(1):30-41. DOI: https://doi.org/10.1159/000527846
Dai C, Jiang M, Sun MJ, Cao Q. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2018;33(5):990-997. DOI: https://doi.org/10.1111/jgh.14121
Kim ES, Lee HS, Kim SK, Kim EY, Jang BI, Kim KO, et al. Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study. Scand J Gastroenterol. 2020;55(2):163-168. DOI: https://doi.org/10.1080/00365521.2020.1714716
Macedo Silva V, Ferreira AI, Lima Capela T, Arieira C, Cúrdia Gonçalves T, Boal Carvalho P, et al. P551 Platelet-to-lymphocyte ratio index for non-invasive assessment of endoscopic activity in small bowel Crohn’s disease: application and prospective validation. Journal of Crohn's and Colitis. 2023;17(Supplement_1):i680-i681. DOI: https://doi.org/10.1093/ecco-jcc/jjac190.0681
Langley BO, Guedry SE, Goldenberg JZ, Hanes DA, Beardsley JA, Ryan JJ. Inflammatory bowel disease and neutrophil-lymphocyte ratio: a systematic scoping review. J Clin Med. 2021;10(18). DOI: https://doi.org/10.3390/jcm10184219
Turpin W, Goethel A, Bedrani L, Croitoru Mdcm K. Determinants of ibd heritability: genes, bugs, and more. Inflamm Bowel Dis. 2018;24(6):1133-1148. DOI: https://doi.org/10.1093/ibd/izy085
Mirkov MU, Verstockt B, Cleynen I. Genetics of inflammatory bowel disease: beyond NOD2. Lancet Gastroenterol Hepatol. 2017;2(3):224-234. DOI: https://doi.org/10.1016/S2468-1253(16)30111-X
Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-164. DOI: https://doi.org/10.1093/ecco-jcc/jjy113
Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54(9):1232-1236. DOI: https://doi.org/10.1136/gut.2004.060228
Livanos AE, Dunn A, Fischer J, Ungaro RC, Turpin W, Lee SH, et al. Anti-Integrin αvβ6 autoantibodies are a novel biomarker that antedate ulcerative colitis. Gastroenterology. 2023;164(4):619-629. DOI: https://doi.org/10.1016/S0016-5085(23)01379-3
Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52(2):171-181. DOI: https://doi.org/10.1373/clinchem.2005.058560
Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42(6):788-791. DOI: https://doi.org/10.1136/gut.42.6.788
Sandborn WJ, Loftus EV, Jr., Colombel JF, Fleming KA, Seibold F, Homburger HA, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2001;7(3):192-201. DOI: https://doi.org/10.1097/00054725-200108000-00003
Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96(3):730-734. DOI: https://doi.org/10.1111/j.1572-0241.2001.03613.x
Koutroubakis IE, Petinaki E, Mouzas IA, Vlachonikolis IG, Anagnostopoulou E, Castanas E, et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96(2):449-454. DOI: https://doi.org/10.1111/j.1572-0241.2001.03524.x
Linskens RK, Mallant-Hent RC, Groothuismink ZM, Bakker-Jonges LE, van de Merwe JP, Hooijkaas H, et al. Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur J Gastroenterol Hepatol. 2002;14(9):1013-1018. DOI: https://doi.org/10.1097/00042737-200209000-00013
Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang H, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996;110(6):1810-1819. DOI: https://doi.org/10.1053/gast.1996.v110.pm8964407
Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47(4):487-496. DOI: https://doi.org/10.1136/gut.47.4.487
Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol. 2004;135(3):490-496. DOI: https://doi.org/10.1111/j.1365-2249.2003.02392.x
Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008;6(10):1105-1111. DOI: https://doi.org/10.1016/j.cgh.2008.04.032
Parkes M, Noor NM, Dowling F, Leung H, Bond S, Whitehead L, et al. PRedicting Outcomes For Crohn's dIsease using a moLecular biomarkEr (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial. BMJ Open. 2018;8(12):e026767. DOI: https://doi.org/10.1136/bmjopen-2018-026767
West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579-589. DOI: https://doi.org/10.1038/nm.4307
Martin JC, Chang C, Boschetti G, Ungaro R, Giri M, Grout JA, et al. Single-cell analysis of Crohn's Disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy. Cell. 2019;178(6):1493-1508.e1420. DOI: https://doi.org/10.1016/j.cell.2019.08.008
Nayar S, Morrison JK, Giri M, Gettler K, Chuang LS, Walker LA, et al. A myeloid-stromal niche and gp130 rescue in NOD2-driven Crohn's disease. Nature. 2021;593(7858):275-281. DOI: https://doi.org/10.1038/s41586-021-03484-5
Štambuk J, Vučković F, Habazin S, Hanić M, Novokmet M, Nikolaus S, et al. Distinct longitudinal changes in immunoglobulin G N-glycosylation associate with therapy response in chronic inflammatory diseases. Int J Mol Sci. 2022;23(15). DOI: https://doi.org/10.3390/ijms23158473
Meserve J, Dulai P. Predicting response to vedolizumab in inflammatory bowel disease. Front Med (Lausanne). 2020;7:76. DOI: https://doi.org/10.3389/fmed.2020.00076
Kim EM, Randall C, Betancourt R, Keene S, Lilly A, Fowler M, et al. Mucosal eosinophilia is an independent predictor of vedolizumab efficacy in inflammatory bowel diseases. Inflamm Bowel Dis. 2020;26(8):1232-1238. DOI: https://doi.org/10.1093/ibd/izz251
Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, et al. Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in ulcerative colitis. Inflamm Bowel Dis. 2019;25(2):410-420. DOI: https://doi.org/10.1093/ibd/izy307
Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, et al. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe. 2017;21(5):603-610.e603. DOI: https://doi.org/10.1016/j.chom.2017.04.010
Lee JW, Plichta D, Hogstrom L, Borren NZ, Lau H, Gregory SM, Tan W, Khalili H, Clish C, Vlamakis H, Xavier RJ. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell host & microbe. 2021 Aug 11;29(8):1294-304. DOI: https://doi.org/10.1016/j.chom.2021.06.019
World Health Organization. Biomarkers and risk assessment: concepts and principles. Environmental health criteria 155. Geneva: World Health Organization; 1993.
Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Leach S, Gorelik A, Liew D, Prideaux L, Lawrance IC. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015 May 1;148(5):938-47. DOI: https://doi.org/10.1053/j.gastro.2015.01.026
Boschetti G, Moussata D, Stefanescu C, Roblin X, Phelip G, Cotte E, Passot G, Francois Y, Drai J, Del Tedesco E, Bouhnik Y. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Official journal of the American College of Gastroenterology| ACG. 2015 Jun 1;110(6):865-72. DOI: https://doi.org/10.1038/ajg.2015.30
Baillet P, Cadiot G, Goutte M, Goutorbe F, Brixi H, Hoeffel C, Allimant C, Reymond M, Obritin-Guilhen H, Magnin B, Bommelaer G. Faecal calprotectin and magnetic resonance imaging in detecting Crohn’s disease endoscopic postoperative recurrence. World Journal of Gastroenterology. 2018 Feb 2;24(5):641. DOI: https://doi.org/10.3748/wjg.v24.i5.641
Jung ES, Lee SP, Kae SH, Kim JH, Kim HS, Jang HJ. Diagnostic accuracy of fecal calprotectin for the detection of small bowel Crohn’s disease through capsule endoscopy: an updated meta-analysis and systematic review. Gut and Liver. 2021 Sep 9;15(5):732. DOI: https://doi.org/10.5009/gnl20249
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Canadian IBD Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
